Impressions from ECM2022
More than 400 participants from 30 countries, 200 high-quality abstracts, and 40 speakers – all with one goal: improving our understanding of the ECM across different diseases!
Researchers, medical doctors, and industry experts from different disease areas traveled to Copenhagen to learn from each other and discuss how to modulate the ECM to benefit patients.
To learn more, download the ECM2022 program below:
Testimonials from ECM2022
Read what our congress attendees had to say about the ECM2022 congress:
“ECM2022 has truly been an ECM knowledge party! Having in the same room all top experts in ECM pharmacology who were coming from different angles to solve the same problem, allowed for very creative discussions and brainstorming. Eliminating the disease-specific barriers allowed for cross-contamination of ideas, from oncology to fibrosis in many different organs, from proteomics, genomic, and transcriptomic datasets to systems for preclinical and translational research. I personally gained a broad insight into what other disease areas than mine look into when they talk about the ECM involvement in the different diseases, and what the challenges and opportunities for pharmacological development are.”
— Federica Genovese, Director of Cardiovascular and Renal Research, Nordic Bioscience, Denmark
“ECM2022 in beautiful Copenhagen delivered new science, new ideas, and networking that led to new colleagues and collaborators. ECM2024 will undoubtedly build on the foundation of 2022, presenting new data, both clinical and pre-clinical, that support the role of the ECM in health and disease; moreover, I expect ECM2024 will add to the growing body of evidence that the ECM is a largely untapped pharmacological target across various organ systems. I’m very much looking forward to being back in Copenhagen!“
— Eric S. White, Clinical Program Lead, Boehringer Ingelheim Pharmaceuticals Inc., USA